CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Sino Biopharmaceutical Limited - 1177 CFD

3.10
0.65%
Market Trading Hours* (UTC) Opens on Monday at 01:30

Mon - Fri: 01:30 - 04:00 05:00 - 08:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.12
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.023404 %
Charges from full value of position ($-4.45)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023404%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.001486 %
Charges from full value of position ($0.28)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.001486%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency HKD
Margin 5%
Stock exchange Hong Kong
Commission on trade 0%

*Information provided by Capital.com

Sino Biopharmaceutical Ltd ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 3.1
Open* 3.1
1-Year Change* -25.12%
Day's Range* 3.04 - 3.12
52 wk Range 2.57-4.97
Average Volume (10 days) 61.39M
Average Volume (3 months) 1.53B
Market Cap 57.16B
P/E Ratio 28.85
Shares Outstanding 18.80B
Revenue 31.37B
EPS 0.11
Dividend (Yield %) 2.63158
Beta 0.61
Next Earnings Date Mar 29, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 23, 2024 3.10 0.02 0.65% 3.08 3.12 3.04
Feb 22, 2024 3.10 0.02 0.65% 3.08 3.12 3.04
Feb 21, 2024 3.08 0.06 1.99% 3.02 3.14 2.98
Feb 20, 2024 3.02 0.00 0.00% 3.02 3.10 2.96
Feb 19, 2024 3.04 -0.04 -1.30% 3.08 3.12 2.98
Feb 16, 2024 3.08 0.18 6.21% 2.90 3.10 2.90
Feb 15, 2024 2.88 0.00 0.00% 2.88 2.92 2.82
Feb 14, 2024 2.86 0.06 2.14% 2.80 2.90 2.76
Feb 9, 2024 2.84 0.00 0.00% 2.84 2.86 2.80
Feb 8, 2024 2.92 0.00 0.00% 2.92 2.98 2.88
Feb 7, 2024 2.94 0.02 0.68% 2.92 2.98 2.90
Feb 6, 2024 2.90 0.18 6.62% 2.72 2.94 2.72
Feb 5, 2024 2.72 -0.04 -1.45% 2.76 2.78 2.64
Feb 2, 2024 2.78 -0.08 -2.80% 2.86 2.94 2.78
Feb 1, 2024 2.84 0.08 2.90% 2.76 2.88 2.76
Jan 31, 2024 2.74 -0.06 -2.14% 2.80 2.82 2.72
Jan 30, 2024 2.80 -0.06 -2.10% 2.86 2.88 2.78
Jan 29, 2024 2.88 0.02 0.70% 2.86 2.90 2.82
Jan 26, 2024 2.80 -0.08 -2.78% 2.88 2.96 2.70
Jan 25, 2024 2.88 0.00 0.00% 2.88 2.90 2.82

Sino Biopharmaceutical Limited Events

Time (UTC) Country Event
Friday, March 29, 2024

Time (UTC)

10:59

Country

HK

Event

Full Year 2023 Sino Biopharmaceutical Ltd Earnings Release
Full Year 2023 Sino Biopharmaceutical Ltd Earnings Release

Forecast

-

Previous

-
Friday, June 14, 2024

Time (UTC)

03:00

Country

HK

Event

Sino Biopharmaceutical Ltd Annual Shareholders Meeting
Sino Biopharmaceutical Ltd Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 28780.4 26861.4 23647.2 24234 20888.6
Revenue 28780.4 26861.4 23647.2 24234 20888.6
Cost of Revenue, Total 5795.51 5332.1 5182.32 4926.27 4196.93
Gross Profit 22984.9 21529.3 18464.9 19307.8 16691.7
Total Operating Expense 22409.8 21610.9 18307.6 18424.9 9366.15
Selling/General/Admin. Expenses, Total 12564 12763.6 11628.6 11797 10268
Interest Expense (Income) - Net Operating -172.512 -1110.37 -963.72 -561.3 -568.428
Unusual Expense (Income) 25.527 639.276 -4.58 -0.903 -6557.24
Other Operating Expenses, Total -55.912 308.971 -161.711 -134.863 -63.724
Operating Income 6370.64 5250.5 5339.65 5809.16 11522.4
Interest Income (Expense), Net Non-Operating -592.034 13322.2 -326.601 -118.565 -93.354
Net Income Before Taxes 5778.6 18572.7 5013.04 5690.59 11429.1
Net Income After Taxes 5002.62 16614.8 4340.67 4787.85 10732.8
Minority Interest -2459.05 -2006.38 -1569.58 -2026.3 -1686.5
Net Income Before Extra. Items 2543.57 14608.4 2771.09 2761.54 9046.35
Net Income 2543.57 14608.4 2771.09 2761.54 9046.35
Income Available to Common Excl. Extra. Items 2543.57 14608.4 2771.09 2761.54 9046.35
Income Available to Common Incl. Extra. Items 2543.57 14608.4 2771.09 2761.54 9046.35
Diluted Net Income 2311.2 14125.9 2771.09 2761.54 9046.35
Diluted Weighted Average Shares 19017.2 19283 18800.3 18811.1 18548.5
Diluted EPS Excluding Extraordinary Items 0.12153 0.73256 0.1474 0.1468 0.48771
Dividends per Share - Common Stock Primary Issue 0.10598 0.06519 0.06172 0.04766 0.04292
Diluted Normalized EPS 0.12269 0.76241 0.14719 0.14743 0.15597
Research & Development 4253.15 3677.26 2626.71 2398.71 2090.57
Dilution Adjustment -232.37 -482.511
Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
Total revenue 15277 13586.7 15193.7 26861.4 7110.79
Revenue 15277 13586.7 15193.7 26861.4 7110.79
Cost of Revenue, Total 3256.5 2835.91 2959.6 5332.1 1337.41
Gross Profit 12020.5 10750.8 12234.1 21529.3 5773.38
Total Operating Expense 11529.3 10636.8 11773 21610.9 5006.58
Selling/General/Admin. Expenses, Total 6444.36 5630.1 6933.9 12703.6 3180.71
Research & Development 2357.26 2204.55 2048.6 3677.26 767.055
Interest Expense (Income) - Net Operating -313.83 17.194 -189.706 -818.075 -181.424
Unusual Expense (Income) -14.761 -1.162 7.288 -3.731 -0.794
Other Operating Expenses, Total -200.24 -49.832 13.321 719.681 -96.374
Operating Income 3747.74 2949.91 3420.73 5250.5 2104.21
Interest Income (Expense), Net Non-Operating -523.575 -925.918 333.884 13322.2 6032.95
Net Income Before Taxes 3224.17 2023.99 3754.61 18572.7 8137.16
Net Income After Taxes 2699.42 1819.4 3183.22 16614.8 7247.19
Minority Interest -1440.64 -1196.86 -1262.18 -2006.38 -680.348
Net Income Before Extra. Items 1258.78 622.533 1921.04 14608.4 6566.84
Net Income 1258.78 622.533 1921.04 14608.4 6566.84
Income Available to Common Excl. Extra. Items 1258.78 622.533 1921.04 14608.4 6566.84
Income Available to Common Incl. Extra. Items 1258.78 622.533 1921.04 14608.4 6566.84
Diluted Net Income 1258.78 551.1 1760.1 14125.9 6566.84
Diluted Weighted Average Shares 18564.2 18911.7 19122.7 19283 19289.1
Diluted EPS Excluding Extraordinary Items 0.06781 0.02914 0.09204 0.73256 0.34044
Dividends per Share - Common Stock Primary Issue 0.01851 0.05299 0.05122 0.03259 0.01663
Diluted Normalized EPS 0.06714 0.02909 0.09237 0.73258 0.34041
Dilution Adjustment -71.433 -160.937 -482.511
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 25934.9 23503.2 22794.2 24913.1 18538.1
Cash and Short Term Investments 16921.7 15794.1 16431.8 19105.6 13022.7
Cash 6413.98 6213.97 6596.5 4340.18 3956.99
Cash & Equivalents 2240.82 3385.56 4027.69 6291.03 2278.04
Short Term Investments 8266.86 6194.51 5807.63 8474.34 6787.64
Total Receivables, Net 6218.71 5537.26 4075.75 3342.97 3865.17
Accounts Receivable - Trade, Net 4638.4 4220.67 2914.08 2712.21 2924.04
Total Inventory 2328.84 1937.74 1880.05 1658.6 1209.16
Prepaid Expenses 465.687 234.127 406.578 805.972 404.009
Other Current Assets, Total 37.116
Total Assets 64064.3 60543.3 47210.4 37514.2 49780.2
Property/Plant/Equipment, Total - Net 9251.18 8516.06 8392.2 7633.22 5804.37
Property/Plant/Equipment, Total - Gross 13858.3 12490.9 11475.9 10013.8 7176.27
Accumulated Depreciation, Total -4607.08 -3974.82 -3083.65 -2380.6 -1371.91
Goodwill, Net 662.611 647.93 88.926 88.926 13897
Intangibles, Net 1251.84 1064.02 924.71 1324.21 8349.17
Long Term Investments 25950.3 25875.1 11215.4 2582.92 1437.27
Other Long Term Assets, Total 1013.41 937.04 3795.02 971.814 1754.29
Total Current Liabilities 20150.7 15345 10943.5 8123.02 9668.62
Accounts Payable 1637.35 1693.15 1947.8 1809.44 1832.17
Accrued Expenses 6299.15 5145.84 4190.39 3560.56 3252.42
Notes Payable/Short Term Debt 136.13 136.13 0 0 0
Current Port. of LT Debt/Capital Leases 9723.84 6585.04 1581.52 689.828 2905.57
Other Current Liabilities, Total 2354.2 1784.86 3223.82 2063.19 1678.46
Total Liabilities 34317.2 30252.2 30463.3 22564.9 20567.4
Total Long Term Debt 4258.12 5685.27 13067.5 7926.07 507.066
Long Term Debt 3933.86 5365.32 12802.6 7884.8 507.066
Deferred Income Tax 831.791 881.59 171.652 423.261 1522.06
Minority Interest 8196.51 7437.91 5672.4 5611.94 8336.69
Other Liabilities, Total 880.146 902.433 608.201 480.652 532.941
Total Equity 29747 30291.1 16747.2 14949.2 29212.8
Common Stock 414.899 415.44 415.895 278.451 278.846
Additional Paid-In Capital 12461.4 12555.7 12668.7 12944.4 13020.5
Retained Earnings (Accumulated Deficit) 19070.3 17926.7 4087.38 2435.23 16462.1
Unrealized Gain (Loss) 93.701 533.078 400.958 37.067 287.199
Other Equity, Total -860.86 -450.393 -355.848 -333.099 -378.576
Total Liabilities & Shareholders’ Equity 64064.3 60543.3 47210.4 37514.2 49780.2
Total Common Shares Outstanding 18468.1 18839.6 18861.5 18882.4 18910.1
Treasury Stock - Common -1432.48 -689.347 -469.944 -412.837 -457.288
Capital Lease Obligations 324.263 319.949 264.861 41.27
Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
Total Current Assets 26977.3 25934.9 25197.8 23503.2 23813.3
Cash and Short Term Investments 15676.4 16921.7 15674.8 15224.6 10443.3
Cash 2821.84 6413.98 4212.46 6213.97 5576.28
Cash & Equivalents 472.126 2240.82 1852.99 3385.56 2452.05
Short Term Investments 12382.4 8266.86 9609.39 5625.01 2415.02
Total Receivables, Net 7188.86 5021.14 5354.76 4625.43 5174.74
Accounts Receivable - Trade, Net 7108.97 4638.4 4947.84 4220.67 5059.33
Total Inventory 2018.5 2328.84 2137.13 1937.74 1731.6
Prepaid Expenses 2093.51 1663.26 2031.04 1715.45 6463.63
Total Assets 65640.9 64064.3 64934.5 60543.3 56206.7
Property/Plant/Equipment, Total - Net 9584.25 9251.18 8772.48 8516.06 8726.67
Goodwill, Net 812.083 662.611 642.552 647.93 906.031
Intangibles, Net 2129.61 1251.84 1214.07 1064.02 915.743
Long Term Investments 24977 25950.3 28168.1 25875.1 17467.1
Other Long Term Assets, Total 1160.69 1013.41 939.52 937.04 4377.86
Total Current Liabilities 26865.4 20150.7 16265.5 15345 11485.5
Accounts Payable 2137.21 1637.35 2676.47 1693.15 1620.73
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 10522.7 9723.84 4118.2 6585.04 1845.84
Other Current Liabilities, Total 14205.5 8789.49 9470.83 7066.83 8018.92
Total Liabilities 35651.6 34317.2 34720.3 30252.2 31631.1
Total Long Term Debt 1031.34 4258.12 7983.31 5685.27 12258.7
Long Term Debt 702.094 3933.86 7627.13 5365.32 11967.4
Capital Lease Obligations 329.246 324.263 356.177 319.949 291.359
Deferred Income Tax 623.447 831.791 1025.56 881.59 773.501
Minority Interest 6469.51 8196.51 8530.46 7437.91 6533.45
Other Liabilities, Total 661.88 880.146 915.477 902.433 579.924
Total Equity 29989.3 29747 30214.2 30291.1 24575.6
Common Stock 414.615 414.899 414.942 415.44 415.895
Retained Earnings (Accumulated Deficit) 19372.6 19070.3 19267.9 17926.7 11801
Treasury Stock - Common -1626.77 -1432.48 -1378.6 -689.347 -469.944
Total Liabilities & Shareholders’ Equity 65640.9 64064.3 64934.5 60543.3 56206.7
Total Common Shares Outstanding 18809.2 18468.1 18815.2 18839.6 18861.5
Additional Paid-In Capital 12420.3 12461.4 12465.8 12555.7 12668.7
Unrealized Gain (Loss) 59.346 93.701 271.418 533.078 517.148
Other Equity, Total -650.759 -860.86 -827.306 -450.393 -357.207
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 5778.6 18572.7 5013.04 5583.82 11429.1
Cash From Operating Activities 6265.15 5366.29 5325.34 5324.63 5094.36
Cash From Operating Activities 906.16 881.414 846.661 634.649 426.151
Amortization 101.686 89.917 763.491 898.351 727.113
Non-Cash Items 642.081 -12870.8 -512.005 -399.094 -6875.88
Cash Taxes Paid 892.085 726.716 959.176 1102.09 838.547
Cash Interest Paid 339.524 179.623 215.307 339.602 153.264
Changes in Working Capital -1163.38 -1306.92 -785.855 -1393.09 -612.103
Cash From Investing Activities -4070.82 -2515.98 -7845.56 -3824.34 -616.1
Capital Expenditures -1402.68 -1741.06 -1495.16 -1481.14 -1565.7
Other Investing Cash Flow Items, Total -2668.14 -774.915 -6350.4 -2343.2 949.599
Cash From Financing Activities -3186.39 -3225.26 2233.19 2800.84 -2177.74
Financing Cash Flow Items -2014.15 -452.366 -1724.7 -1512.43 -1167.66
Total Cash Dividends Paid -1267.62 -938.489 -1187.02 -819.688 -710.328
Issuance (Retirement) of Debt, Net 962.991 -1501.48 5340.28 5165.01 304.665
Foreign Exchange Effects 47.322 -649.711 280.015 95.054 242.465
Net Change in Cash -944.732 -1024.66 -7.016 4396.18 2542.99
Issuance (Retirement) of Stock, Net -867.613 -332.93 -195.373 -32.05 -604.419
Dec 2022 Jun 2022 Dec 2021 Jun 2021 Mar 2021
Cash From Operating Activities 6265.15 3948.94 5366.29 2335.55
Changes in Working Capital 6265.15 3948.94 5366.29 2335.55
Cash From Investing Activities -4070.82 -5989.66 -2515.98 -4055.97
Other Investing Cash Flow Items, Total -2827.49 -5362.69 -2515.98 -4055.97
Cash From Financing Activities -3186.39 -1460.53 -3225.26 -761.689
Financing Cash Flow Items -3367.9 -249.354 -3225.26 -761.689
Foreign Exchange Effects 47.322 -32.85 -649.711 -113.766
Net Change in Cash -944.732 -3534.09 -1024.66 -2595.87
Capital Expenditures -1243.32 -626.972
Issuance (Retirement) of Stock, Net -867.613 -809.316
Issuance (Retirement) of Debt, Net 1049.12 -401.857
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Tse (Eric S Y) Individual Investor 21.5412 4050000000 0 2022-12-31
France Investment China 1 Group Ltd Corporation 12.1229 2279254761 0 2023-06-30
Tse (Ping) Individual Investor 8.8207 1658403124 27000000 2023-07-06 LOW
Cheng (Cheung Ling) Individual Investor 4.718 887034750 7000000 2023-04-04
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.6965 318957763 -1764000 2023-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.0584 198993951 -5565000 2023-09-30 LOW
First Sentier Investors (Hong Kong) Limited Investment Advisor 1.0019 188360500 -3018000 2023-07-31 LOW
Tse (Hsin Stephen) Individual Investor 0.9268 174247000 0 2022-12-31
Bosera Asset Management Co., Ltd. Investment Advisor 0.7277 136825000 48812000 2023-06-30 MED
State Street Global Advisors Asia Ltd. Investment Advisor/Hedge Fund 0.6734 126615223 4027416 2023-09-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.5832 109645878 -17217700 2022-12-31 LOW
APG Asset Management N.V. Pension Fund 0.5599 105263158 -13607922 2023-03-31 LOW
Hang Seng Investment Management Ltd. Investment Advisor 0.4592 86341681 8534944 2023-09-30 LOW
BlackRock Advisors (UK) Limited Investment Advisor/Hedge Fund 0.385 72390477 196000 2023-09-30 LOW
California Public Employees' Retirement System Pension Fund 0.3818 71777747 -5538000 2022-06-30 LOW
HSBC Global Asset Management (Hong Kong) Limited Investment Advisor 0.3517 66124984 0 2022-12-31 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.3506 65908990 -5518500 2023-09-30 LOW
Schroder Investment Management (Hong Kong) Ltd. Investment Advisor/Hedge Fund 0.288 54143000 54143000 2023-07-31 LOW
China Asset Management Co., Ltd. Investment Advisor 0.2512 47229988 187088 2023-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.2365 44458499 0 2023-09-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Sino Biopharmeceutical Company profile

Sino Biopharmaceutical Limited, researches, develops, manufactures, and sells Chinese medicines and chemical medicines in Hong Kong, Mainland China, and internationally. The company operates in Modernized Chinese Medicines and Chemical Medicines, Investment, and Others segments. Its principal products include hepatitis medicines, such as Runzhong dispersible tablets, Tianqingganmei injections, Tianqingganping enteric capsules, Tianding tablets, Mingzheng capsules, and Ganlixin injections and capsules; and cardio-cerebral medicines comprising Kaishi injections, Yilunping and Tuotuo tablets, Tianqingning injections, and Beraprost Sodium tablets; and oncology medicines consisting of Zhiruo, Saiweijian, Tianqingyitai, and Qingweike injections, as well as Shoufu and Yinishu tablets, and Gelike capsules. The company's principal products also include Analgesic medicines, such as Kaifen injections and Zepusi Flurbiprofen Cataplasms; Orthopedic medicines, which comprise New Ossified Triol capsules and Jiuli tablets; anti-infectious medicines, including Tiance injections and Tianjie tablets; parenteral nutritious medicines, such as Xinhaineng and Fenghaineng fructose injections; respiratory system medicines, including Tianqingsule inhalation powder and Chia Tai Suke tablets; and anorectal medicines comprising Aisuping injections and Getai tablets. In addition, it develops medicines for liver, tumor, cardio-cerebral, analgesia, respiratory system, and orthopedic diseases; engages in the retail and distribution of pharmaceutical products; provides medical management consultancy services; and manufactures, sells, and distributes health food products, as well as is involved in optometry for optical glasses and sale of ophthalmic products. Further, the company provides research and development, medical technology development, and outpatient and surgical procedure services. The company was incorporated in 2000 and is headquartered in Wanchai, Hong Kong.
Industry: Pharmaceuticals (NEC)

湾仔港湾道1号会展广场辨公大楼41楼09室
HK

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

US100

17,914.30 Price
-0.300% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 22:00 (UTC)
Spread 7.0

BTC/USD

51,616.75 Price
+1.190% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Oil - Crude

76.56 Price
-2.240% 1D Chg, %
Long position overnight fee 0.0163%
Short position overnight fee -0.0382%
Overnight fee time 22:00 (UTC)
Spread 0.030

Gold

2,035.76 Price
+0.560% 1D Chg, %
Long position overnight fee -0.0185%
Short position overnight fee 0.0103%
Overnight fee time 22:00 (UTC)
Spread 0.50

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading